Zimmer Partners LP Sells 154,200 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Zimmer Partners LP cut its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 73.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 56,900 shares of the company's stock after selling 154,200 shares during the period. Zimmer Partners LP owned approximately 0.10% of Structure Therapeutics worth $1,543,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Spire Wealth Management purchased a new position in Structure Therapeutics in the fourth quarter worth about $243,000. JPMorgan Chase & Co. raised its holdings in Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after buying an additional 25,500 shares during the last quarter. Mariner LLC purchased a new position in Structure Therapeutics in the fourth quarter worth about $665,000. Barclays PLC raised its holdings in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after buying an additional 31,815 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Structure Therapeutics by 4.1% in the fourth quarter. Invesco Ltd. now owns 371,767 shares of the company's stock worth $10,082,000 after buying an additional 14,559 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR stock traded down $0.10 during trading hours on Friday, reaching $24.55. The company had a trading volume of 267,802 shares, compared to its average volume of 932,263. The business has a fifty day moving average price of $21.53 and a 200-day moving average price of $25.94. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The firm has a market cap of $1.41 billion, a PE ratio of -33.18 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Analyst Upgrades and Downgrades

GPCR has been the subject of several recent analyst reports. Citigroup initiated coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, HC Wainwright reduced their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $79.86.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.